MedTrace Logo

Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.

NCT04572620 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-10-01

No results posted yet for this study

Summary

The rationale for this retrospective study is to evaluate the efficacy and safety of abatacept and rituximab treatment of ILLD in a cohort of pediatric patients with different forms of PID, who received one of the two therapy regimens predominantly based on the lesions histopathology.

Conditions

  • Interstitial Lymphocytic Lung Disease

Interventions

DRUG

Rituximab

375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.

DRUG

Abatacept

10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.

Sponsors & Collaborators

  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04572620 on ClinicalTrials.gov